JP6133308B2 - 凍結乾燥リポソーム - Google Patents

凍結乾燥リポソーム Download PDF

Info

Publication number
JP6133308B2
JP6133308B2 JP2014537142A JP2014537142A JP6133308B2 JP 6133308 B2 JP6133308 B2 JP 6133308B2 JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014537142 A JP2014537142 A JP 2014537142A JP 6133308 B2 JP6133308 B2 JP 6133308B2
Authority
JP
Japan
Prior art keywords
liposomes
liposome
composition
drug
lyophilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532623A (ja
JP2014532623A5 (https=
Inventor
ドナ キャブラル−リリー，
ドナ キャブラル−リリー，
ローレンス メイヤー，
ローレンス メイヤー，
ポール ターディ，
ポール ターディ，
デイビッド ワトキンス，
デイビッド ワトキンス，
イ ジェン，
イ ジェン，
Original Assignee
セレーター ファーマシューティカルズ インコーポレイテッド
セレーター ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6133308(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セレーター ファーマシューティカルズ インコーポレイテッド, セレーター ファーマシューティカルズ インコーポレイテッド filed Critical セレーター ファーマシューティカルズ インコーポレイテッド
Publication of JP2014532623A publication Critical patent/JP2014532623A/ja
Publication of JP2014532623A5 publication Critical patent/JP2014532623A5/ja
Application granted granted Critical
Publication of JP6133308B2 publication Critical patent/JP6133308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2014537142A 2011-10-21 2012-10-15 凍結乾燥リポソーム Active JP6133308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
US61/550,047 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017074348A Division JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム

Publications (3)

Publication Number Publication Date
JP2014532623A JP2014532623A (ja) 2014-12-08
JP2014532623A5 JP2014532623A5 (https=) 2015-10-15
JP6133308B2 true JP6133308B2 (ja) 2017-05-24

Family

ID=48141268

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014537142A Active JP6133308B2 (ja) 2011-10-21 2012-10-15 凍結乾燥リポソーム
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム

Country Status (22)

Country Link
US (5) US10028912B2 (https=)
EP (2) EP3572071A1 (https=)
JP (6) JP6133308B2 (https=)
KR (5) KR102452305B1 (https=)
CN (2) CN108853031A (https=)
AU (1) AU2012326370C9 (https=)
BR (1) BR112014009305B1 (https=)
CA (1) CA2852777C (https=)
DK (1) DK2768484T3 (https=)
ES (1) ES2750368T3 (https=)
FR (1) FR19C1063I2 (https=)
HR (1) HRP20191683T1 (https=)
HU (2) HUE045978T2 (https=)
IL (1) IL232161B (https=)
LU (1) LUC00135I2 (https=)
NL (1) NL301016I2 (https=)
NO (1) NO2019041I1 (https=)
PL (1) PL2768484T3 (https=)
PT (1) PT2768484T (https=)
RU (1) RU2648753C2 (https=)
SI (1) SI2768484T1 (https=)
WO (1) WO2013059133A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017160211A (ja) * 2011-10-21 2017-09-14 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292567B2 (en) 2013-08-13 2025-06-01 Univ Northwestern Peptide conjugated particles
WO2016033384A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
KR20180016347A (ko) * 2015-04-13 2018-02-14 파운테인 테크놀로지스 인터내셔널, 엘엘씨 초-소형 지질 구조체의 생산을 위한 단일-단계 방법
SMT202100196T1 (it) 2015-07-22 2021-05-07 Nitto Denko Corp Composizioni e metodi per forme liofile di nanoparticelle
CN108778260A (zh) * 2015-11-11 2018-11-09 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
SG10201913504XA (en) 2016-02-26 2020-03-30 Massachusetts Gen Hospital Medical ice slurry production and delivery systems and methods
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN111093623A (zh) * 2017-07-10 2020-05-01 免疫疫苗技术公司 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途
EP3856198A4 (en) 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
ES3049663T3 (en) * 2019-06-28 2025-12-17 Univ Texas Method of reconstituting liposomal annamycin
WO2021016457A1 (en) * 2019-07-24 2021-01-28 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
EP0208764A4 (en) * 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
WO1990003795A1 (en) * 1988-10-05 1990-04-19 Vestar, Inc. Method of making liposomes with improved stability during drying
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
WO1997029782A1 (en) 1996-02-19 1997-08-21 Nycomed Imaging A/S Thermally stabilized contrast agent
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
DE60014093T2 (de) 1999-07-16 2005-02-03 Alza Corp., Mountain View Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2462376C (en) 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
CA2467064C (en) 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
DE60222580T2 (de) 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
US20040265368A1 (en) * 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
WO2005102359A1 (en) * 2004-04-22 2005-11-03 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
AU2005302255A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
EP1817005A1 (en) 2004-11-18 2007-08-15 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
AU2006306108B2 (en) 2005-10-25 2012-10-04 Jazz Pharmaceuticals Therapeutics, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
EP4046640A1 (en) * 2007-02-16 2022-08-24 Rotalec IP Holdings LLC Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
ES2550759T3 (es) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
US8486924B2 (en) 2007-11-28 2013-07-16 Celator Pharmaceuticals, Inc. Taxane delivery system
EP2344161B1 (en) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
PT2508170E (pt) 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
EP3572071A1 (en) * 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017160211A (ja) * 2011-10-21 2017-09-14 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム
JP2018150342A (ja) * 2011-10-21 2018-09-27 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム

Also Published As

Publication number Publication date
US20190070112A1 (en) 2019-03-07
US10166184B2 (en) 2019-01-01
AU2012326370C9 (en) 2023-05-18
EP2768484B1 (en) 2019-07-24
CA2852777A1 (en) 2013-04-25
KR20200057104A (ko) 2020-05-25
IL232161B (en) 2019-07-31
JP6592556B2 (ja) 2019-10-16
HK1201039A1 (en) 2015-08-21
LUC00135I2 (https=) 2021-02-12
RU2648753C2 (ru) 2018-03-28
EP2768484A1 (en) 2014-08-27
JP2014532623A (ja) 2014-12-08
JP2024045183A (ja) 2024-04-02
KR20140092323A (ko) 2014-07-23
KR102113753B1 (ko) 2020-05-21
KR102452305B1 (ko) 2022-10-07
US20140255475A1 (en) 2014-09-11
AU2012326370B2 (en) 2017-06-01
FR19C1063I1 (fr) 2019-11-22
FR19C1063I2 (fr) 2020-10-30
KR20220141906A (ko) 2022-10-20
US10835492B2 (en) 2020-11-17
RU2014120475A (ru) 2015-11-27
EP3572071A1 (en) 2019-11-27
JP2022033892A (ja) 2022-03-02
KR102284689B1 (ko) 2021-08-02
RU2018107407A (ru) 2019-02-25
AU2012326370A2 (en) 2014-06-12
NL301016I1 (nl) 2019-10-30
RU2018107407A3 (https=) 2021-05-04
KR20210095746A (ko) 2021-08-02
KR102024836B1 (ko) 2019-09-24
JP6359717B2 (ja) 2018-07-18
CN104114156A (zh) 2014-10-22
CN108853031A (zh) 2018-11-23
US20230172855A1 (en) 2023-06-08
JP2017160211A (ja) 2017-09-14
JP2020007367A (ja) 2020-01-16
PL2768484T3 (pl) 2019-12-31
PT2768484T (pt) 2019-10-28
IL232161A0 (en) 2014-05-28
NO2019041I1 (no) 2019-11-25
DK2768484T3 (da) 2019-10-07
CA2852777C (en) 2020-10-27
HUS1900047I1 (hu) 2019-11-28
JP2018150342A (ja) 2018-09-27
AU2012326370C1 (en) 2023-03-30
SI2768484T1 (sl) 2019-12-31
BR112014009305A2 (pt) 2017-04-11
JP7476161B2 (ja) 2024-04-30
NL301016I2 (nl) 2020-04-16
WO2013059133A1 (en) 2013-04-25
LUC00135I1 (https=) 2019-10-25
ES2750368T3 (es) 2020-03-25
AU2012326370A1 (en) 2014-06-05
BR112014009305B1 (pt) 2023-01-24
KR20190111139A (ko) 2019-10-01
US10028912B2 (en) 2018-07-24
HRP20191683T1 (hr) 2019-12-13
US20180161273A1 (en) 2018-06-14
US20210169803A1 (en) 2021-06-10
HUE045978T2 (hu) 2020-01-28
EP2768484A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
JP6592556B2 (ja) 凍結乾燥リポソーム
KR101209496B1 (ko) 나노입자 제제를 보관하는 방법
RU2780489C2 (ru) Лиофилизированные липосомы
HK1201039B (en) Lyophilized liposomes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161012

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20161012

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20161017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170419

R150 Certificate of patent or registration of utility model

Ref document number: 6133308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250